Abstract:Background: Leukemia inhibitory factor (LIF) is a multifunctional member of the IL-6 cytokine family that activates downstream signaling pathways by binding to the heterodimer consisting of LIFR and gp130 on the cell surface. Previous research has shown that LIF is highly expressed in various tumor tissues (e.g. pancreatic cancer, breast cancer, prostate cancer, and colorectal cancer) and promotes cancer cell proliferation, migration, invasion, and differentiation. Moreover, the overexpression of LIF correlates with poor clinicopathological characteristics. Therefore, we hypothesized that LIF could be a promising target for the treatment of cancer. In this work, we developed the antagonist antibody 1G11 against LIF and investigated its anti-tumor mechanism and its therapeutic efficacy in mouse models. Results: A series of single-chain variable fragments (scFvs) targeting LIF were screened from a naive human scFv phage library. These scFvs were reconstructed in complete IgG form and produced by the mammalian transient expression system. Among the antibodies, 1G11 exhibited the excellent binding activity to human, cynomolgus monkey and mouse LIF. Functional analysis demonstrated 1G11 could block LIF binding to LIFR and inhibit the intracellular STAT3 phosphorylation signal. Interestingly, 1G11 did not block LIF binding to gp130, another LIF receptor that is involved in forming the receptor complex together with LIFR. In vivo, intraperitoneal administration of 1G11 inhibited tumor growth in CT26 and MC38 models of colorectal cancer. IHC analysis demonstrated that p-STAT3 and Ki67 were decreased in tumor tissue, while c-caspase 3 was increased. Furthermore, 1G11 treatment improves CD3+, CD4 + and CD8 + T cell infiltration in tumor tissue. Conclusions: We developed antagonist antibodies targeting LIF/LIFR signaling pathway from a naive human scFv phage library. Antagonist anti-LIF antibody exerts antitumor effects by specifically reducing p-STAT3. Further studies revealed that anti-LIF antibody 1G11 increased immune cell infiltration in tumor tissues.

Internal Image Anti-Idiotypic Antibody: A New Strategy for the Development a New Category of Prolactin Receptor (PRLR) Antagonist

Preparation and characterization of a novel monoclonal antibody against human PD-1

Generation and Characterization of Four Novel Monoclonal Antibodies Against Human Programmed Death-1 Molecule.

Anti-idiotypic Antibody: A New Strategy for the Development of a Growth Hormone Receptor Antagonist

A Neutralizing Prolactin Receptor Antibody Whose In Vivo Application Mimics the Phenotype of Female Prolactin Receptor-Deficient Mice

The Activation and Differential Signalling of the Growth Hormone Receptor Induced by Pgh or Anti-Idiotypic Monoclonal Antibodies in Primary Rat Hepatocytes

A novel bispecific antibody targeting CD3 and prolactin receptor (PRLR) against PRLR-expression breast cancer

Generation Of Internal Image Monoclonal Anti-Idiotypic Antibodies Against Idiotypic Antibodies To Gp5 Antigen Of Porcine Reproductive And Respiratory Syndrome Virus

A Novel Mechanism of hPRL-G129R, a Prolactin Antagonist, Inhibits Human Breast Cancer Cell Proliferation and Migration

Functional genomic characterization of a synthetic anti-HER3 antibody reveals a role for ubiquitination by RNF41 in the anti-proliferative response

Discovery of the Improved Antagonistic Prolactin Variants by Library Screening.

Differential Intracellular Signalling Properties of the Growth Hormone Receptor Induced by the Activation of an Anti-Ghr Antibody

Anti-EGFL7 antibodies inhibit rat prolactinoma MMQ cells proliferation and PRL secretion

Preparation and Immunological Characterization of Anti-idiotypic Antibody for Porcine Growth Hormone

Preparation and application of anti-human PD-L1 monoclonal antibodies

Production of monoclonal antibodies against GPCR using cell-free synthesized GPCR antigen and biotinylated liposome-based interaction assay

Engineering synthetic antibody binders for allosteric inhibition of prolactin receptor signaling

Anti-GnRH Receptor Monoclonal Antibody, GHR106 is First-inClass GnRH Antagonist

Generating a Bispecific Antibody Drug Conjugate Targeting PRLR and HER2 with Improving the Internalization

Preparation of a novel monoclonal antibody against active components of PHA-L from Phaseolus vulgaris and its functional characteristics

Antagonist anti-LIF antibody derived from naive human scFv phage library inhibited tumor growth in mice